Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on oncology that completed its public debut through a merger with Panacea Acquisition Corp. II, a blank-check vehicle sponsored by Panacea Capital Group. The SPAC priced its initial public offering in 2021, and the business combination closed in early 2022, bringing Nuvation Bio into the public markets under its current ticker. The company is developing a pipeline of novel cancer therapeutics and operates in the clinical-stage oncology sector. An 8-K current report was filed with the SEC on April 10, 2024, under accession number 0001193125-24-091875. For complete filing history, sponsor details, and deal analytics on NUVB and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.